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Objective: True splenic artery aneurysms (SAAs) are a rare but potentially fatal pathology. For many years, open repair
(OPEN) and conservative management (CONS) were the treatments of choice, but throughout the last decade endo-
vascular repair (EV) has become increasingly used. The purpose of the present study was to perform a systematic review
and meta-analysis evaluating the outcomes of the three major treatment modalities (OPEN, EV, and CONS) for the
management of SAAs.
Methods: A systematic review of all studies describing the outcomes of SAAs treated with OPEN, EV, or CONS was
performed using seven large medical databases. The Preferred Reporting Items for Systematic Reviews andMeta-Analyses
(PRISMA) guidelines were followed to ensure a high-quality review. All articles were subject to critical appraisal for
relevance, validity, and availability of data regarding characteristics and outcomes. All data were systematically pooled,
and meta-analyses were performed on several outcomes, including early and late mortality, complications, and number of
reinterventions.
Results: Original data of 1321 patients with true SAAs were identiﬁed in 47 articles. OPEN contained 511 patients
(38.7%) in 31 articles, followed by 425 patients (32.2%) in CONS in 16 articles and 385 patients (29.1%) in EV in 33
articles. The CONS group had fewer symptomatic patients (9.5% vs 28.7% in OPEN and 28.8% in EV; P < .001) and
fewer ruptured aneurysms (0.2% vs 18.4% in OPEN and 8.8% in EV; P < .001), but no signiﬁcant differences were found
in existing comorbidities. CONS patients were usually older and had smaller-sized aneurysms than patients in the OPEN
and EV groups. The only identiﬁed difference in baseline characteristics between OPEN and EV was the number of
ruptured aneurysms (18.4% vs 8.8%; P < .001). OPEN had a higher 30-day mortality than EV (5.1% vs 0.6%; P < .001),
whereas minor complications occurred in a larger number of the EV patients. EV required more reinterventions per year
(3.2%) compared with OPEN (0.5%) and CONS (1.2%; P < .001). The late mortality rate was higher in patients treated
with CONS (4.9% vs 2.1% in OPEN and 1.4% in EV; P [ .04).
Conclusions: EV of SAA has better short-term results compared with OPEN, including signiﬁcantly lower perioperative
mortality. OPEN is associated with fewer late complications and fewer reinterventions during follow-up. Patients treated
with CONS showed a higher late mortality rate. Ruptured SAAs are predictors of a signiﬁcantly higher perioperative
mortality compared with nonruptured SAAs in the OPEN and EV groups. (J Vasc Surg 2014;60:1667-76.)the Section of Vascular Surgery, Yale University School of Medicine,
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://dx.doi.org/10.1016/j.jvs.2014.08.067True splenic artery aneurysms (SAAs) are a rare but
potentially fatal pathology. The splenic artery is considered
aneurysmal when the size of the artery is >1 cm in diam-
eter. True SAAs are deﬁned as expansions of all wall layers,
whereas pseudoaneurysms are deﬁned as expansions of the
artery with focal disruption of the arterial wall.1 Although
rare, SAAs are the third most common abdominal aneurysms
after aortic and iliac artery aneurysms and account for
almost all visceral artery aneurysms.2 Previous studies
have shown a high risk for SAA rupture when the aneu-
rysm measures >2 cm.3,4 Although most SAAs are asymp-
tomatic, they have the potential to rupture, which can
result in life-threatening complications.2-5 This emphasizes
the importance of continued surveillance of SAAs and
timely intervention if the SAA reaches the threshold limit.1667
JOURNAL OF VASCULAR SURGERY
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gical repair was not reported until 1940.7 Open repair
(OPEN) or conservative management (CONS) was the
treatment of choice for many years. During the last decade,
however, endovascular repair (EV) of SAAs has been
increasingly used with good short-term results.8-11 Because
this disease is rare, most studies are retrospective, reporting
only a small number of patients, and therefore, no Level 1
evidence is available.
With the more frequent use of diagnostic tests, there
has been an increase in the detection of SAAs and, thus,
an increasing need for clear directives. The current general
consensus has been to intervene in all symptomatic patients
and aneurysms >2 cm in diameter, but no clear guidelines
for indications of treatment have been reported. All three
management options have pros and cons. OPEN has
shown excellent long-term results but high perioperative
mortality.12-15 EV has shown low short-term morbidity
and mortality but a higher reintervention rate as result of
long-term complications.8-11 CONS has no immediate
procedural risk but an increasing risk of aneurysm rupture
potentially resulting in life-threatening hemorrhage.2-5
However, most evidence is disseminated over several
smaller studies over a broad period of time, and no clear
overviews, guidelines, or management recommendations
are available.
The purpose of the present study was to perform a sys-
tematic review and meta-analysis evaluating the outcomes
of the three treatment modalitiesdOPEN, EV, and
CONSdfor the management of SAAs, taking into account
the clinical presentation.
METHODS
Literature search. The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines were used to perform this systematic review and meta-
analysis.16 To identify all articles describing treatment of
SAAs, MEDLINE, EMBASE, Web of Science, Scopus,
PubMed as supplied by the publisher, Cochrane Library
Central, and Google Scholar were systematically searched
through December 12, 2013. No publication date re-
striction was applied.
The following search string was used for EMBASE:
(“spleen artery aneurysm”/de or ((“spleen artery”/de or
spleen/de) and (“aneurysm surgery”/exp or aneurysm/
exp)) or ((spleen or splenic) NEAR/3 aneurysm*):ab,ti)
and (therapy/exp or therapy:lnk or surgery/exp or surger-
y:lnk or procedures/de or (therap* or treat* or curing or
cure or repair or technique* or procedure* or equipment*
or surg* or operat*):ab,ti). This resulted in 1121 articles. A
similar search string was used for other search engines. De-
tails of search strings and number of articles can be found in
the Appendix (online only). We identiﬁed 2702 articles,
and after removal of duplicate articles, 1490 unique articles
remained.
Selection of articles. Review of titles and abstracts was
performed independently by two investigators (W.H. and
A.L.). For a report to be excluded, both reviewers had toagree that the article was ineligible for inclusion. Disagree-
ments between reviewers were discussed and resolved by
consensus. Articles were included if (1) original data of
characteristics and outcomes of true SAAs were reported,
(2) they described OPEN, EV, or CONS management,
and (3) reported at least 10 patients, because case reports
and case series have the tendency toward publication
bias, only reporting successful cases.17 Exclusion criteria
included (1) articles without original data, (2) articles
speciﬁcally reporting pregnant patients with SAAs because
of the different pathophysiology, (3) not describing
OPEN, EV, or CONS management, (4) describing false/
pseudoaneurysms, (5) if there was no clear distinction be-
tween splenic aneurysms and visceral aneurysm, and (6) if
no useful information regarding the outcomes was pre-
sented. To prevent inclusions of duplicate cases, articles
published by identical authors or institutions were studied
in detail, and the most recent article was included.
Because administrative data (eg, Medicare ﬁles) are
considered to be less reliable and less consistent and could
have been published previously in other included articles,
these articles were not included. To identify additional rele-
vant articles, references of included articles were searched
manually and retrieved three additional articles. A total of
47 relevant articles were identiﬁed and included in the ﬁnal
selection (Fig 1).
Data extraction. Two independent investigators
(W.H., A.L.) analyzed the included articles and extracted
the data. All extracted characteristics and outcomes were
systematically included in a database. If a variable was
described only for the whole group in an article that
described multiple types of treatment, but not speciﬁc for
OPEN, EV, or CONS, this variable was not included
in the analysis. The variables extracted included year of
publication, institution, number of patients, number of an-
eurysms, age, sex, size of the SAA, percentage of symptom-
atic patients, type of symptoms, percentage of ruptures,
number of patients with hypertension, hyperlipidemia, dia-
betes mellitus, coronary artery disease, number of patients
smoking, type of treatment, type of intervention, type of
surgery, number of splenectomies, elective or emergency
cases, technical success, conversion from EV to OPEN,
30-day minor complications, type of morbidity, major
complications, 30-day mortality, cause of death <30 days,
late complications, late (>30 days) mortality, number of
reinterventions, hospital length of stay in days, length of
follow-up in months, number lost to follow-up, and overall
survival. Patient selection was based on the recommenda-
tions of the Quality of Reporting of Meta-analyses
(QUOROM) statement.18 Additional information on the
exact techniques used for OPEN and EV is beyond the
scope of this report, but the relevant information is
addressed in the referenced article.19 Original data of 1321
patients with true SAAs treated with OPEN, EV, or CONS
were analyzed.
Statistical analyses. Statistical analyses were per-
formed using IBM SPSS 22.0 software (IBM Corp,
Armonk, NY), Review Manager (RevMan) 5.2 software
Records identified through 
database searching (n = 2702)
Additional records identified 
through other sources (n = 3)
Records after duplicates 
removed (n = 1493)
Abstracts screened
(n = 1493)
Records excluded
(n = 1278)
Full-text articles 
assessed for eligibility
(n = 215)
Full-text articles excluded 
(n = 168)
No useful information 51
Reviews / Expert-opinion 5
Case-report 36
Conference abstract 11
Only laparoscopic 4
Only pseudoaneurysms 6
Only pregnant women 3
Only liver transplants 2
< 10 patients 21
Not OPEN, EV or CONS 7
CPT coding 2
Not most recent data 3
Conference poster 4
Surgical picture 2
Other 11
Studies included in 
analysis (n = 47)
Only OPEN
(n = 8)
Only EV
(n = 16)
OPEN + EV
(n = 7)
OPEN + CONS
(n = 6)
OPEN + 
EV + 
CONS
(n = 10)
Only CONS
(n = 0)
EV + CONS
(n = 0)
OPEN
(n = 31)
EV
(n = 33)
CONS
(n = 16)
Total number of articles describing outcomes for:
Fig 1. Flow diagram shows literature search and selection, following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines for splenic artery aneurysms (SAAs). CONS, Conservative man-
agement; EV, endovascular repair; OPEN, open repair.
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Fig 2. Cumulative number of patients treated with open repair (OPEN; red), endovascular repair (EV; black), or
conservative management (CONS; blue) for splenic artery aneurysms (SAAs) by year of publication.
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Centre, Copenhagen, Denmark), and Excel 2010 software
(Microsoft Corp, Redmond, Wash). Continuous variables
are described using means and standard deviations, if
possible, and categoric factors are reported in frequencies
and percentages. Some of the percentages were calculated
into rates per year (eg, for the reinterventions) by using
the equation: [rate ¼ ln (1  prob)/time]. Continuous
variables were compared using the t-test for two groups
or analysis of variance for more than two groups. Categoric
characteristics and outcomes were used to compare vari-
ables and outcomes among OPEN, EV, and CONS using
the c2 test or the Fisher exact test when the expected num-
ber was fewer than ﬁve.
Adjustment for learning curve and ruptures. Given
the importance of the time of publication, an additional
analysis was performed for OPEN vs EV only using data
from articles published after 2000. The year 2000 was cho-
sen as the cutoff point because there was still a learning curve
for the EV group before 2000. Only a few small case studies
or case reports were published before 2000 describing the
EV of SAAs. Comparison was also performed between pa-
tients who presented with ruptured SAA and patients who
were not reported as presenting with ruptured SAAs.
RESULTS
Literature search. Original data of 1321 patients with
true SAAs were identiﬁed in 47 articles. OPEN contained
the largest number of patients, at 511 (38.7%), followed
by CONS with 425 (32.2%) and EV with 385 (29.1%).
In total, 31 articles described characteristics and outcomes
for patients treated with OPEN,2-5,12-15,20-42 33 articles for
EV,1,3-5,8-11,13-15,20-26,32-35,43-53 and 16 for CONS.2-5,20-31Details of the number of articles and patients are shown in
Fig 1. Fig 2 shows the distribution of the different types of
treatment by publication date. An increase of patients
treated with EV can be seen after 2000: only 2% of all
treated aneurysms were managed with EV in 1999 and was
w25% in 2000 to 2002, w50% in 2003 to 2009, and
w70% in 2010 to 2013. Availability of the studied variables
in the analyzed articles are reported in Table I.
Study characteristics. Baseline characteristics, fre-
quencies, and signiﬁcance levels are given in Table II. Pa-
tients in the CONS group were older than those in the
OPEN and EV groups, with a mean age of 61.4 years vs
56.3 years in OPEN and 56.7 years in EV, and the CONS
group contained a higher number of female patients
(75.1%) compared with OPEN (63.9%) and EV (60.0%;
P ¼ .001). The CONS group had patients with a smaller
aneurysm size (2.1 cm) compared with OPEN (3.1 cm)
and EV (3.0 cm), a smaller number of symptomatic pa-
tients (9.5% vs 28.7% in OPEN and 28.8% in EV; P <
.001), and less ruptured aneurysms (0.2% vs 18.4% in
OPEN and 8.8% in EV; P < .001). Owing to the lack of
reported standard deviations, ranges, and interquartile
ranges in the evaluated reports, no standard deviation and,
therefore, no statistical signiﬁcance could be calculated for
age and size of aneurysm.
There were no signiﬁcant differences in the presence of
different comorbidities (hypertension, hyperlipidemia, dia-
betes mellitus, coronary artery disease, and smoking)
among the groups. The baseline characteristics were not
signiﬁcantly different between the OPEN and EV group,
except for the number of ruptured aneurysms, which was
higher in the OPEN group than in the EV group (18.4%
vs 8.8%; P < .001).
Table I. Availability of data in the evaluated reports
Variable available
All patients
(N ¼ 1321), No. (%)
OPEN (n ¼ 511),
No. (%)
EV (n ¼ 385),
No. (%)
CONS (n ¼ 425),
No. (%)
Age 1277 (97) 506 (99) 384 (99) 387 (91)
Gender 847 (64) 341 (67) 265 (69) 241 (57)
Aneurysm
Number 1321 (100) 511 (100) 385 (100) 425 (100)
Size 999 (76) 347 (68) 297 (77) 355 (84)
Location 448 (34) 183 (36) 219 (57) 46 (11)
Presence of
Symptoms 1070 (81) 415 (81) 278 (72) 377 (89)
Rupture 1212 (92) 456 (89) 354 (92) 402 (95)
Hypertension 656 (50) 209 (41) 113 (29) 334 (79)
Hyperlipidemia 397 (30) 77 (15) 86 (22) 234 (55)
Diabetes 472 (36) 113 (22) 103 (27) 256 (60)
Coronary artery disease 434 (33) 92 (18) 102 (26) 240 (56)
Smoking 459 (35) 98 (19) 102 (26) 259 (61)
Type of intervention 896/896 (100) 511 (100) 385 (100) NA
Elective/emergency 779/896 (87) 439 (86) 340 (88) NA
Technical success 882/896 (98) 498 (97) 384 (99) NA
Splenectomy 870/896 (97) 511 (100) 359 (93) NA
Conversion 375/385 (97) NA 375 (97) NA
Thirty-day morbidity 1231 (93) 438 (86) 378 (98) 415 (98)
Thirty-day mortality 1307 (99) 498 (97) 384 (99) 425 (100)
Length of
Hospital stay 233/896 (26) 64 (13) 169 (44) NA
Follow-up 1104 (84) 377 (74) 342 (89) 385 (91)
Lost to follow-up 560 (42) 119 (23) 227 (59) 214 (50)
Late complications 909 (69) 335 (66) 354 (92) 220 (52)
Late mortality 918 (69) 334 (65) 349 (91) 235 (55)
Reinterventions 1211 (92) 450 (88) 384 (99) 377 (89)
Survival 895 (68) 317 (62) 241 (63) 337 (79)
CONS, Conservative management; EV, endovascular repair; NA, not applicable; OPEN, open repair.
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group was resection of the aneurysm combined with sple-
nectomy in most patients, followed by reconstruction of
the splenic artery. The preferred method of EV was embo-
lization, followed by stenting of the SAA (Table II).
Early outcomes. Technical success was achieved in
97.8% of the OPEN cases and in 95.2% of the EV cases
(Table III). Conversion to open surgery was necessary
in 1.8% of the EV cases to successfully exclude the aneu-
rysm. The 30-day mortality in the OPEN group was much
higher compared with the EV patients (5.1% vs 0.6%;
P < .001), whereas a larger number of patients treated with
EV experienced minor complications (wound infection,
postembolization syndrome). The incidence of major long-
term complications was low and was similar, with 1.1% for
OPEN and 0.8% for EV. The mean hospital length of stay
was longer in the OPEN group (9.8 days) compared with
the EV group (2.0 days).
Late outcomes. The mean length of follow-up was
much shorter for EV than for OPEN and CONS, at
30.8 months, 61.2 months, and 61.8 months, respectively,
due to the relatively new procedures and techniques of EV.
During these follow-up periods, more late complications
developed in patients in the EV group and they required
more reinterventions than the OPEN and CONS patients.
Patients in the CONS group, however, had a higher rate oflate mortality compared with OPEN and EV (Table III).
An average of 3.7% complications per year developed in the
EV patients, and 3.2% required reinterventions per year.
Patients initially treated with CONS required 1.2% in-
terventions per year, whereas the OPEN group only
required 0.5% reinterventions per year (P < .001).
Adjusting for the learning curve. More minor com-
plications and fewer late deaths after OPEN were reported
after 2000 compared with the period before 2000
(Table IV). All the other outcomes were not signiﬁ-
cantly different statistically. This comparison was not
performed for patients treated with EV because there were
insufﬁcient cases before to 2000 to perform a meaningful
analysis (n ¼ 5).
Outcomes between OPEN and EV after 2000 are re-
ported in Table V and show the same outcomes as re-
ported for the outcomes of all time periods combined,
which were given in Table III. Technical success (P ¼
.018) and 30-day mortality (P < .001) were higher
in the OPEN group. The number of acute minor compli-
cations (P ¼ .012), number of late complications
(P < .001), and number of reinterventions (P ¼ .007)
were higher in the EV group.
Ruptured vs unruptured SAAs. Because the only dif-
ference in the baseline characteristics between OPEN and
EV was the number of patients with ruptured SAAs, the
Table II. Baseline characteristics of patients with splenic artery aneurysms (SAAs)
P value
Characteristic
OPEN (n ¼ 511),
No. (%) or mean
EV (n ¼ 385),
No. (%) or mean
CONS (n ¼ 425),
No. (%) or mean All groups OPEN vs EV
Age, years 56.3 56.7 61.4 ea ea
Gender, % female 218 (63.9) 159 (60.0) 181 (75.1) .001 .322
Aneurysms/patient, No. 1.16 1.06 1.13 ea ea
Aneurysm size, cm 3.1 3.0 2.1 ea ea
Location
Proximal 27 (14.8) 41 (18.7) 4 (10.3) .316 .291
Middle 50 (27.3) 71 (32.4) 11 (28.3) .523 .267
Distal/hilar 106 (57.9) 107 (48.9) 24 (61.5) .114 .070
Symptomatic 119 (28.7) 80 (28.8) 35 (9.5) <.001 .977
Ruptured SAA 84 (18.4) 31 (8.8) 1 (0.2) <.001 <.001
Hypertension 84 (40.1) 54 (47.7) 154 (46.2) .299 .189
Hyperlipidemia 18 (23.7) 28 (33.1) 68 (29.1) .426 .194
Diabetes 13 (11.3) 13 (12.5) 26 (10.0) .782 .801
Coronary artery disease 15 (16.0) 15 (14.7) 50 (21.0) .343 .758
Smoking 29 (29.7) 19 (18.8) 55 (21.1) .139 .070
Type of intervention
Ligation 63 (12.3) NA NA
Reconstruction 100 (19.6) NA NA
Resection 51 (10.0) NA NA
Splenectomy 291 (56.9) 6 (1.6) NA
Stent NA 13 (3.4) NA
Embolization NA 365 (94.8) NA
Other 6 (1.2) 1 (0.3) NA
CONS, Conservative management; EV, endovascular repair; NA, not applicable; OPEN, open repair.
aOwing to the lack of reported standard deviations, ranges, and interquartile ranges in the evaluated reports, no standard deviations and, therefore, no sta-
tistical signiﬁcance could be calculated for age, aneurysm size, and aneurysm number.
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aneurysms was speciﬁcally analyzed. Data were available for
810 patients describing ruptured or unruptured SAAs and
the 30-day mortality. These results are shown as a sub-
analysis in Table V and demonstrate that a higher mortality
was reported for ruptured and unruptured patients in the
OPEN group compared with the EV group.DISCUSSION
The results of this meta-analysis show that EV of SAA
has better short-term results than OPEN. However,
OPEN is associated with fewer late complications and rein-
terventions during follow-up. Patients who were treated
with CONS were not at immediate risk of perioperative
death but showed a higher late mortality rate. These
patients were usually older, had smaller aneurysms than pa-
tients in the OPEN and EV groups, and had fewer symp-
toms and ruptures. Except for the difference in number
of ruptured SAAs, there were no other differences between
the OPEN and EV group, thus making them eligible for
comparison.
SAAs account for up to 75% of all visceral artery aneu-
rysms and are more commonly reported in female patients
than in male patients at a ratio of 4:1.3,14,54 We observed a
higher number of female patients in the articles used in this
meta-analysis, with women accounting for 66.0% of the pa-
tients. With a mean age of 58.0 for the entire group, SAAs
are predominantly found in elderly women. Why SAAspredominate in women is not exactly clear, but a hormonal
contribution has been postulated.55
This meta-analysis, with >1300 included patients, is by
far the most extensive analysis of patients with true SAAs to
date. Given the rarity of the disease, most published articles
are, not surprisingly, small retrospective studies. The
strength of a meta-analysis is that by pooling many studies,
the effective sample size is greatly increased, and therefore,
more characteristics and outcomes can be evaluated.56
There are, however, some limitations. First, data collec-
tionwas restricted to information available in the existing liter-
ature, and information about many variables could not be
retrieved for all of the patients; for example, data regarding
the sizeof the aneurysmwereonly available for76%ofpatients.
Regrettably, this is inherent to meta-analyses in general. In
addition, we rely completely on published reports on whether
aneurysms are true or false. Articles reporting false aneurysms,
or in case this was not clear in the report, were excluded.
The second limitation is that no statistical comparison
could be performed for several characteristics, including
age and aneurysm size, due to the lack of comprehensive
statistical information in the articles. To perform an accu-
rate statistical test, one needs at least the standard devia-
tions, ranges, or interquartile ranges when combining the
means, and unfortunately, these were poorly described in
the literature. When crudely comparing the patient ages
and aneurysm sizes among the groups, OPEN and EV
were performed in very similar patient populations consist-
ing of younger patients (56.3 years vs 56.7 years) with
Table III. Outcomes of patients with splenic artery aneurysms (SAAs) after treatment
Outcome
P value
OPEN (n ¼ 511),
No. (%) or mean
EV (n ¼ 385),
No. (%) or mean
CONS (n ¼ 425),
No. (%) or mean All groups OPEN vs EV
Technical success 487 (97.8) 366 (95.2) NA NA .041
Conversion 0 (0.0) 7 (1.8) NA NA NA
Complications
Minor 49 (11.3) 95 (25.1) NA NA <.001
Major 3 (1.1) 3 (0.8) NA NA .690
Thirty-day mortality 25 (5.1) 2 (0.6) 2 (0.5) <.001 <.001
Length of
Hospital stay, days 9.8 2.03 NA ea ea
Follow-up, months 61.2 30.8 61.8 ea ea
Late complications 9 (2.5) 34 (9.1) 2 (0.8) <.001 <.001
Late mortality 7 (2.1) 5 (1.4) 11 (4.9) .040 .510
Reinterventions 9 (2.4) 30 (7.9) 22 (5.8) .004 <.001
CONS, Conservative management; EV, endovascular repair; NA, not applicable; OPEN, open repair.
aOwing to the lack of reported standard deviations, ranges, and interquartile ranges in the evaluated reports, no standard deviations and, therefore, no sta-
tistical signiﬁcance could be calculated for length of hospital stay and follow-up.
Table V. Outcomes of patients with splenic artery
aneurysms (SAAs) after treatment after the year 2000
Outcome after 2000
OPEN (n ¼ 283),
No. (%) or mean
EV (n ¼ 380),
No. (%) or
mean P value
Technical success 279 (98.6) 362 (95.2) .018
Conversion 0 (0) 7 (1.8) NA
Complications
Minor 39 (16.9) 95 (25.3) .012
Major 3 (1.4) 3 (0.9) .407
Thirty-day mortality 14 (5.0) 2 (0.6) <.001
Unruptured 5 (2.6) 0 (0.0) .008
Ruptured 9 (20.4) 2 (6.7) .196
Length of
Hospital stay, days 9.8 2.03 ea
Follow-up, months 54.2 30.7 ea
Late complications 9 (3.3) 34 (9.2) .006
Late mortality 1 (0.4) 3 (1.2) .405
Reinterventions 8 (2.9) 30 (8.0) .007
EV, Endovascular repair; NA, not applicable; OPEN, open repair.
aOwing to the lack of reported standard deviations, ranges, and interquartile
ranges in the evaluated reports, no standard deviations and, therefore, no
statistical signiﬁcance could be calculated for length of hospital stay and
follow-up.
Table IV. Outcomes of patients with splenic artery
aneurysms after open repair (OPEN) before and after the
year 2000
OPEN outcomea
Before 2000
(n ¼ 228),
No. (%)
or mean
After 2000)
(n ¼ 283),
No. (%)
or mean P value
Technical success 208 (96.7) 279 (98.6) .221
Conversion 0 (0) 0 (0) NA
Complications
Minor 10 (4.9) 39 (16.9) <.001
Major 0 (0) 3 (1.4) .566
Thirty-day mortality 11 (5.2) 14 (5.0) .932
Length of
Hospital stay, days NA 9.8 eb
Follow-up, months 72.8 54.2 eb
Late complications 0 (0) 9 (3.3) .122
Late mortality 6 (7.1) 1 (0.4) .001
Reinterventions 1 (1.0) 8 (2.9) .457
NA, Not applicable.
aAnalysis by year of publication only performed for patients treated with
OPEN because of the lack of patients treated with endovascular repair (EV)
before 2000 (n ¼ 5).
bOwing to the lack of reported standard deviations, ranges, and interquartile
ranges in the evaluated reports, no standard deviations and, therefore, no
statistical signiﬁcance could be calculated for length of hospital stay and
follow-up.
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(61.4 years and 2.1 cm).
Another limitation of this systematic review is that only
publications with $10 patients were included. As a result,
no case reports or case series were included, which reduced
the number of patients included in this review but
increased the data quality. Furthermore, because case re-
ports and case series usually report successful interventions,
whereas retrospective reviews with >10 patients will
include the failures as well, this approach reduced selection
bias and publication bias.17 The 10 articles describing allthree treatment modalities contributed 515 patients (40%
of all patients).
Before 2000, when EV treatment was ﬁrst being
described, only CONS or OPEN treatment were reported.
To highlight this, none of the articles described only
CONS and only eight described only OPEN treatment. Ar-
ticles are more robust when they report multiple treatment
options, because the outcomes will be exactly deﬁned;
however, this is not always the case. In addition, our re-
ported outcomes are objective (mortality, reintervention,
etc), and do not include subjective parameters, such as
pain for example, where you can expect reporting bias.
To strengthen the results presented here, additional an-
alyses were performed by year of publication (before and
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ruptured aneurysms. Because postoperative care has likely
improved considerably during the past decade, comparing
results of EV (almost all of which were performed after
2000) with results of OPEN performed during last 50 years
would not be reasonable.
Initially, we also planned to perform an additional
analysis of outcomes for patients with and without
splenectomy. The comparison was, unfortunately, not
possible because splenectomy was not well described in
the included studies. Most studies described how many
patients had a splenectomy and the number of patients
who had complications or died, but failed to report the
morbidity and mortality and long-term survival. Because
of this, a Kaplan-Meier survival curve could not be
created.
Combining the perioperative mortality and long-term
mortality showed that OPEN has a higher combined mor-
tality compared with EV and CONS. This is also likely to
be the result of a higher number of patients with ruptured
aneurysms. In addition, EV has a lower combined mortality
compared with CONS, which is likely the result of the in-
clusion of older patients with more comorbidities in the
CONS group compared with the EV group.
The last important limitation is our inability to stratify
patients by the location of the SAA because location was re-
ported in only 34% of the patients. In addition, detailed
outcomes related to the location of the SAA were available
in only two articles, preventing us from performing an
extensive analysis.45,48 The incidence of splenectomies in
the series was high (56.9%). Because the location of the
aneurysm on the splenic artery was not known in most
cases, commenting on whether some of these splenecto-
mies could be avoided is not possible. It has been reported
in series of splenorenal bypass procedures that, provided
that the splenic artery is transected proximal to the left gas-
troepiploic artery, this is well tolerated and no splenectomy
is indicated.57
Finally, although some studies reported that the post-
embolization syndrome (PES) occurred more frequently
in treated aneurysms located in the splenic hilum, no studies
reported differences inmortality between aneurysms located
in different segments of the splenic artery.5,25,49,52
One ﬁnal caveat is in regards to the type of articles
included in this meta-analysis. Because most articles in
our meta-analysis were retrospective, treatment of SAA
was not randomized and the indication for treatment
might have been primarily based on the risk of future
events. The resulting imbalance in the underlying risk pro-
ﬁle between the EV and OPEN groups can generate bias
by indication. However, the only difference in baseline
characteristics between the groups was the number of
ruptured aneurysms, and an analysis stratiﬁed for rupture
vs nonrupture was performed to prevent this type of bias.
There is no Level 1 evidence comparing the treatment
options for the management of true SAAs, and this current
study provides the most extensive overview of the current
literature, which can guide the management by the vascularsurgeon. The only prospective randomized comparison for
the management of SAAs was a comparison of open and
laparoscopic intervention for true SAAs.42 However, we
did not include laparoscopic intervention in our analysis
because only two studies of laparoscopic intervention re-
ported more than >10 patients, which we concluded
would increase the uncertainty for the pooled outcomes
and decrease the quality of this meta-analysis. Laparoscopic
repair of the SAA is the most performed laparoscopic inter-
vention of all aneurysms because of the easy-to-access loca-
tion.58 The largest study of laparoscopic interventions,
consisting of 16 patients, reported no conversions, need
for reoperation or related deaths.59
In addition, out meta-analysis consisted of 1 RCT (low
power/quality, Level 2 evidence), 10 Level 2 studies, 13
Level 3 studies, and 24 Level 4 studies and is the best ev-
idence available at the moment.
The interesting fact that more minor complications
developed in people in the EV group than in the OPEN
group has not been extensively discussed in previous re-
ports. No signiﬁcant difference was found between the
number of major complications between OPEN and EV.
Still, most reviews report a “higher morbidity and mortal-
ity” for patients treated with OPEN.54,60 In this meta-
analysis, we included PES as a minor complication, which
can be responsible for this higher number of minor compli-
cations. PES, which can present as fever, abdominal pain,
pleural effusion, and possibly pancreatitis after splenic
infarction, is the most common complication after EV
and can potentially require prolonged hospitalization.
PES is reported in up to 30% of patients, which is similar
to the 25.1% reported in this meta-analysis.44 We note
that most OPEN repairs included splenectomy as part of
the procedure, which prevents PES.
This meta-analysis, which pooled the characteristics
and outcomes of all the available data in the literature is
descriptive rather than prescriptive. Therefore, it is not
possible to exactly guide treatment based on this meta-
analysis. The current general consensus is to treat all pa-
tients with symptomatic and ruptured aneurysms and
asymptomatic patients with a SAA >2.0 cm. In addition,
treatment is recommended in women of childbearing age
who present with aneurysms <2 cm in diameter in anticipa-
tion of future pregnancy.49 However, whether these treat-
ment recommendations are similar for elderly or high-risk
patients is not clear. Future research, with a more
individual-based approach should give these answers.
In addition, there is currently no evidence to support
the superiority of stenting or embolization. Surgical excision
of the SAA is recommended when the pancreas is not close
to the aneurysm, both proximally and distally. Proximal and
distal ligation of the artery is recommended when the aneu-
rysm is close to the pancreas. Splenectomy will be required if
the aneurysm is located in the hilus of the spleen.61
A lot of questions remain regarding the optimal treat-
ment of true SAAs, and one cannot make recommenda-
tions tailored to the patient on the basis of these results.
The decision about which intervention would be preferred
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90-year-old high-risk man. Furthermore, morbidity, mor-
tality, and number of reinterventions are not the only
important considerations, but also the quality of life, asso-
ciated interventional and lifetime costs, and expected rein-
terventions over the remaining lifetime. The three major
treatment modalities all have pros and cons and a well-
conducted risk-beneﬁt analysis could be performed with a
clinical decision model to create patient-tailored recom-
mendations for treatment of true SAAs.
Finally, the long-term importance of splenectomy on,
for example, postsplenectomy infection and prevention of
sepsis in asplenic patients, should be assessed in future
research. Other future research projects could focus on
the effect of aneurysm size on late mortality in patients
treated with CONS.
CONCLUSIONS
EV of the SAA has better short-term results compared
with OPEN, including signiﬁcantly lower perioperative
mortality; however, OPEN is associated with fewer late
complications and reinterventions during follow-up. Pa-
tients treated with CONS showed a higher late mortality
rate. Ruptured SAAs are predictors for a signiﬁcant higher
perioperative mortality compared with nonruptured SAAs
in the OPEN and EV group. The results of this meta-
analysis show that SAAs >2 cm should be treated, given
the good short-term and long-term results. EV repair has
the best outcomes and should be the treatment of choice
if the splenic artery has a suitable anatomy for EV repair.
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